Private funding sees IcanoMAB launch to develop precision mAbs

IcanoMAB, a privately-funded biotech based in Germany, has launched to develop novel precision canonical antibodies for the treatment of cancer, immune-system related diseases and COVID-19.

The company has secured three clinical candidates in IND-enabling stage and funding from MAB Discovery, originally generating the licensed antibodies from a novel antibody discovery platform.

After 10 years of more than 50 successful monoclonal antibody discovery projects with large Pharma and mid- and large-size Biotech companies, MAB Discovery sold its antibody production platform and laboratory to BioNTech (NASDAQ: BNTX) in 2019.

At the end of 2019, a pre-clinical project in the field of Immuno-oncology was licensed to a Top Pharma company.

IcanoMAB will use the proceeds to advance the clinical candidates to allow IND-enabling activities and respective partnering activities with selected third parties.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news